Design Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
RESTORE-FA is progressing with key data expected in the second half of the year, while exploratory studies in FECD and DM1 advance using the GeneTAC platform. The company is well-funded into 2029, aiming for clinical proof of concept in major indications.
-
The company presented updates on its small molecule genetic medicine platform, highlighting clinical progress in FA, FECD, and DM1. Key data readouts are expected in the second half of this year and next year, with strong financial resources supporting ongoing trials.
Fiscal Year 2025
-
The company is advancing small molecule therapies for monogenic diseases, with clinical programs in Friedreich's ataxia, Fuchs' corneal dystrophy, and DM1. New formulations have improved safety and exposure, with key data readouts expected in 2026–2027. Cash runway extends into 2029.
-
DT-818 for DM1 will enter clinical trials in 2026, with promising preclinical results and broad tissue targeting. DT-216P2 for FA is off clinical hold, with RESTOR-FA data expected in late 2026, and DT-168 for Fuchs is in a novel biomarker study. Cash runway extends into 2029.
-
GeneTACs are advancing as selective small molecules for monogenic diseases, with clinical progress in Friedreich's ataxia and Fuchs' corneal dystrophy. Improved formulations and biomarker strategies support ongoing trials, and strong financials enable continued development.
-
The company is advancing a differentiated small molecule genomic medicine platform with clinical programs in Friedreich ataxia and Fuchs endothelial corneal dystrophy. New formulations address prior safety and exposure issues, with key data readouts expected in 2026.
-
Gene tag molecules offer a novel approach to modulate gene expression for monogenic diseases, with lead programs DT-216P2 for Friedreich's ataxia and DT-168 for Fuchs' corneal dystrophy advancing in clinical development. Additional pipeline assets target Huntington's and myotonic dystrophy.
-
Multiple gene-targeted programs are advancing, with a new DT-216P2 formulation for Friedreich ataxia addressing prior limitations and aiming for patient studies in mid-2025. Fuchs program phase I data is expected soon, and strong cash reserves support progress into 2029.
Fiscal Year 2024
-
DT-216 v2 is set for healthy volunteer studies in early 2025, aiming to address prior safety and exposure issues in FA. The Fuchs program advances with a novel eyedrop and a large observational study, targeting a major unmet need. Both programs are positioned for key data and phase 2 planning in 2025.
-
The company is advancing a differentiated genomic medicine platform with four lead programs targeting severe monogenic diseases. Clinical trials for FECD and FA are planned for 2025, supported by a strong cash position and a focus on rapid patient impact.
-
The company is advancing small molecule therapies that modulate gene expression for genetic diseases, with lead programs in Friedreich's ataxia, myotonic dystrophy, and Fuchs' corneal dystrophy. New formulations improve drug exposure, and clinical milestones are expected in 2024.